Taysha Gene Therapies (TSHA) News Today $2.06 -0.21 (-9.25%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceCanaccord Genuity Group raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday.November 15 at 9:53 AM | marketbeat.comQ3 2024 Taysha Gene Therapies Inc Earnings CallNovember 14 at 12:59 PM | finance.yahoo.comTaysha Gene Therapies: Promising Progress and Financial Stability Justify Buy RatingNovember 14 at 12:59 PM | markets.businessinsider.comBuy Rating Justified for Taysha Gene Therapies Amid Promising TSHA-102 Developments and Upcoming CatalystsNovember 14 at 12:59 PM | markets.businessinsider.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - What's Next?Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - What's Next?November 14 at 11:58 AM | marketbeat.comTaysha Gene Therapies: Promising Developments and Strong Financial Position Support Buy RatingNovember 14 at 7:58 AM | markets.businessinsider.comNeurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" (TSHA)Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.November 14 at 7:05 AM | marketbeat.comTaysha Gene Therapies Advances in Rett Syndrome TrialsNovember 14 at 2:56 AM | markets.businessinsider.comTaysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comTaysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comPositive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over NeurogeneNovember 13, 2024 | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.38 Consensus Price Target from AnalystsNovember 13, 2024 | americanbankingnews.comPiper Sandler Releases a Buy Rating on Taysha Gene Therapies (TSHA)November 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Taysha Gene Therapies Amid Promising TSHA-102 Trial ResultsNovember 13, 2024 | markets.businessinsider.comJMP Securities Reaffirms "Market Outperform" Rating for Taysha Gene Therapies (NASDAQ:TSHA)JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday.November 12, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Taysha Gene Therapies (NASDAQ:TSHA)Cantor Fitzgerald reiterated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday.November 12, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday.November 12, 2024 | marketbeat.comTaysha Gene Therapies (TSHA) Scheduled to Post Quarterly Earnings on WednesdayTaysha Gene Therapies (NASDAQ:TSHA) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comTaysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13November 6, 2024 | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from AnalystsShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year targetNovember 6, 2024 | marketbeat.comOptimistic Buy Rating for Taysha Gene Therapies Amid Promising Rett Syndrome Study OutcomesNovember 5, 2024 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comTaysha Gene Therapies (TSHA) Gets a Buy from Cantor FitzgeraldNovember 1, 2024 | markets.businessinsider.comTaysha Gene Therapies to present biodistribution data from AAV9 analysisOctober 22, 2024 | markets.businessinsider.comTaysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT CongressOctober 22, 2024 | globenewswire.comTaysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome DataOctober 14, 2024 | seekingalpha.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Position Lowered by Renaissance Technologies LLCRenaissance Technologies LLC reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 87.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,100 shares of the company's stock afOctober 14, 2024 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have earned a consensus rating of "Buy" from the eight analysts that are currently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price target amonOctober 12, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Stock, Insider Trading ActivityOctober 7, 2024 | benzinga.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | globenewswire.comIs Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?October 3, 2024 | uk.finance.yahoo.com454,464 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 454,464 shares of the company's stock, valued at approximately $1,01September 22, 2024 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 6, 2024 | globenewswire.com3 Penny Stocks to Buy With $100September 5, 2024 | 247wallst.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) have been given an average rating of "Buy" by the nine brokerages that are presently covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy rating. The average 12 month target price amonAugust 23, 2024 | marketbeat.comChardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Equities researchers at Chardan Capital lifted their FY2024 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a research report issued to clients and investors on Wednesday, August 14th. Chardan Capital analyst Y. LAugust 19, 2024 | marketbeat.comTaysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 18, 2024 | finance.yahoo.comTSHA Sep 2024 1.000 put (TSHA240920P00001000)August 16, 2024 | finance.yahoo.comCantor Fitzgerald Brokers Raise Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a research report issued to clients and investors on Tuesday, August 13th. Cantor Fitzgerald analyst K.August 15, 2024 | marketbeat.comBuy Rating for Taysha Gene Therapies Backed by Extended Cash Runway and Promising Trial ProspectsAugust 14, 2024 | markets.businessinsider.comMaintained Buy Rating on Taysha Gene Therapies Amid Progress and Solid FinancialsAugust 14, 2024 | markets.businessinsider.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Lowered to $6.00 at Canaccord Genuity GroupCanaccord Genuity Group cut their price target on Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday.August 14, 2024 | marketbeat.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed for Taysha Gene Therapies Amid Strong Financials and Promising Clinical TrialsAugust 13, 2024 | markets.businessinsider.comChardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)Chardan Capital reissued a "buy" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday.August 13, 2024 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPSTaysha Gene Therapies (NASDAQ:TSHA - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. During the same period in the prior year, the business posted ($0.38) earnings per share.August 13, 2024 | marketbeat.comBuy Rating Affirmed for Taysha Gene Therapies Amid Strategic Planning and Potential Drug EfficacyAugust 13, 2024 | markets.businessinsider.comVanguard Group Inc. Trims Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)Vanguard Group Inc. reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 4.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,917,414 shares of the company's stock after selling 278,153 sAugust 13, 2024 | marketbeat.comTaysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.com Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now TSHA Media Mentions By Week TSHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSHA News Sentiment▼0.630.55▲Average Medical News Sentiment TSHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSHA Articles This Week▼233▲TSHA Articles Average Week Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VXRT News PASG News EOLS News MESO News CRGX News IGMS News CGEM News PAHC News ETNB News PRTA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSHA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSHA Stock Alerts